JW Lifescience Corporation
234080.KS
Get informed when a big investor buys or sells
+ FollowMarket Cap$169.4B
Close$
Share Statistics
| Market cap | $169.40 Billion |
|---|---|
| Enterprise Value | $192.76 Billion |
| Dividend Yield | $550.00 (5.03%) |
| Earnings per Share | $1847.38 |
| Beta | 0.24 |
| Outstanding Shares | 15,835,000 |
Return
| Return on Equity | 11.47% |
|---|---|
| Return on Assets | 8.51% |
| Return on Invested Capital | 13.87% |
Valuation & Multiples
| P/E Ratio | 6.51 |
|---|---|
| PEG | -22.98 |
| Price to Sales | 0.68 |
| Price to Book Ratio | 0.76 |
| Enterprise Value to Revenue | 0.76 |
| Enterprise Value to EBIT | 5.78 |
| Enterprise Value to Net Income | 7 |
| Total Debt to Enterprise | 0.17 |
| Debt to Equity | 0.14 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 12, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
$66.70 B
Average shareholder expectationNext Earnings Call
Expected Date
November 16, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
$66.70 B
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About JW Lifescience Corporation
319 employees
CEO: Seong-Nam Cha JW Life Science Corp. manufactures intravenous fluids. Its products include basic IV, nutrition, special fluids, irrigation agents and dialysis solutions. The company was founded on May 10, 1994 and is headquartered in Dangjin-si, South Korea.